you are viewing a single comment's thread.
full pricing for the secondary is $5.90/shthis is an overreaction, stock should settle down around 6.50i would take the profits and re-enterafter the pullback. 7.xx is too high.
U do nor know the pipeline.IMHO
doesn't matter, their closest drug candidate is still in the middle of Phase 2. It's going to be a long time before this co books any earnings, which is why they had to sell more stock to raise funds.